Bioaegis Therapeutics Inc., of Morristown, N.J., said it closed a $4.1 million equity round and has begun patient enrollment in a phase Ib/IIa study of recombinant plasma gelsolin (rhu-pGSN) in community-acquired pneumonia in Australasia. The company is focused on an approach to address infectious, inflammatory and degenerative diseases through a portfolio built around rhu-pGSN technology.